JOURNAL OF CELLULAR AND MOLECULAR MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2022-10-07 ms5000000525566741

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：生物学
经验分享：ADM: Admin, WOA
Under Review
这个状态是编辑在审查吧，不是送外审。

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2022-09-22 ms8000001960429576

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;分子医学;Cancer
经验分享：文章接受后，多久有do i号

51 0

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2022-05-10 frank0404

修回一个多月了，审稿中，着急用啊=-=

55 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2021-11-10 ms4000002065293393

underreview了五个月了。。。。。想撤稿了

82 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2021-11-16 吉川李春代

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：分子生物学;分子医学
经验分享：under review了快四个月了，我的天，想撤稿

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2021-10-22 流年似水30

偏重的研究方向：头颈肿瘤
经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了

80 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2021-11-29 146e9ba1m68暂无昵称

审稿速度:6.0
偏重的研究方向：免疫
经验分享：三个月了还在under review 太难受了

62 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2022-01-19 916603706

11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了

50 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2020-12-25 填写后不可修改

它又上了吉林大学第一附属医院的黑名单警示。

10 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2092346, encodeId=1fc120923466d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：生物学 经验分享：ADM: Admin, WOA Under Review 这个状态是编辑在审查吧，不是送外审。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2315573864, createdName=ms5000000525566741, createdTime=Fri Oct 07 20:25:56 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089768, encodeId=b4a52089e688a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;分子医学;Cancer 经验分享：文章接受后，多久有do i号, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d68124001, createdName=ms8000001960429576, createdTime=Thu Sep 22 14:16:00 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218509, encodeId=8cbb1218509a5, content=修回一个多月了，审稿中，着急用啊=-=, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3995578333, createdName=frank0404, createdTime=Tue May 10 18:07:23 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069011, encodeId=cb1c106901195, content=underreview了五个月了。。。。。想撤稿了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=ms4000002065293393, createdTime=Wed Nov 10 16:52:39 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1070717, encodeId=3a7610e07173e, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学;分子医学 经验分享：under review了快四个月了，我的天，想撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d545592040, createdName=吉川李春代, createdTime=Tue Nov 16 11:48:07 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063002, encodeId=4be51063002ce, content=偏重的研究方向：头颈肿瘤 经验分享：8个半月，under review 还有一样的么，要不是不着急文章早疯了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210525/e0df933ff66e428cb399aaaad5bc69a5/1b5ae6fcfbe843fd90c6131f6a934dfd.jpg, createdBy=32215499944, createdName=流年似水30, createdTime=Fri Oct 22 18:28:36 CST 2021, time=2021-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074962, encodeId=dd2810e4962a7, content=审稿速度:6.0 偏重的研究方向：免疫 经验分享：三个月了还在under review 太难受了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5ca85176505, createdName=146e9ba1m68暂无昵称, createdTime=Mon Nov 29 07:26:56 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186213, encodeId=5b06118621325, content=11月8日投稿，12月19日大修，没要求补实验，只是一些解释或者衔接的小问题，1月11日修回，1月19日变成awaiting AE assignment了，有没有大神解释下这是什么情况啊，好害怕啊，指着它毕业了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b882996665, createdName=916603706, createdTime=Wed Jan 19 23:15:24 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=910855, encodeId=414691085560, content=它又上了吉林大学第一附属医院的黑名单警示。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Fri Dec 25 12:25:02 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602116, encodeId=c19f6021168f, content=请问accept,complete final file updates之后还有哪些步骤呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200710/10bd1d998fe04dde83a0c3bd61e524c7/007df3473bde4e64badd227207aff0c3.jpg, createdBy=c0b12110388, createdName=@gns, createdTime=Fri Jun 12 13:12:34 CST 2020, time=2020-06-12, status=1, ipAttribution=)]

2020-06-12 @gns

请问accept,complete final file updates之后还有哪些步骤呢

59 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务